Company Overview and News

 
2 Oversold Small Biotech Stocks

19h seekingalpha
Both appear to have favorable risk/reward profiles at current trading levels and have some upcoming potential catalysts.

2
Zynerba Pharmaceuticals Appoints John P. Butler to Board of Directors

2018-04-16 globenewswire
DEVON, Pa., April 16, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare neurological and psychiatric disorders with high unmet medical needs, today announced the appointment of John Butler to its board of directors.

2
JLLM / Jolley Marketing, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-04-13 fintel.io
Jolley Marketing, Inc. (OTC:JLLM) has 2 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 86,324,551 shares. Largest shareholders include Warbington Timothy, and Herbst Timothy.

 
PAGS / PagSeguro Digital Ltd. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-04-13 fintel.io
PagSeguro Digital Ltd. (NYSE:PAGS) has 1 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 12,819,592 shares. Largest shareholders include Ameriprise Financial Inc.

 
NM / Navios Maritime Holdings, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-04-13 fintel.io
Navios Maritime Holdings, Inc. (NYSE:NM) has 93 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 67,358,894 shares. Largest shareholders include Frangou Angeliki, BlackRock Inc., Warlander Asset Management, LP, Royce & Associates LLC, Parametric Portfolio Associates Llc, Renaissance Technologies LLC, PenderFund Capital Management Ltd.

 
GLLK / Gold Lakes Corp. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-04-13 fintel.io
Gold Lakes Corp. (OTC:GLLK) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include .

 
RFL.WI / Rafael Holdings, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-04-12 fintel.io
Rafael Holdings, Inc. (AMEX:RFL.WI) has 1 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 2,626,428 shares. Largest shareholders include Jonas Howard S.

 
RFIL / RF Industries, Ltd - Stock Institutional Ownership and Shareholders - Fintel.io

2018-04-12 fintel.io
RF Industries, Ltd (NASDAQ:RFIL) has 23 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 2,242,015 shares. Largest shareholders include Renaissance Technologies LLC, Hirschman Orin, BlackRock Inc., Dimensional Fund Advisors Lp, Grt Capital Partners L.l.c., Vanguard Group Inc, California Public Employees Retirement System, Thompson Davis & Co.

 
IEA / Infrastructure & Energy Alternatives, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-04-12 fintel.io
Infrastructure & Energy Alternatives, Inc. (NASDAQ:IEA) has 2 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 3,364,423 shares. Largest shareholders include M Iii Sponsor I Llc, and Greenhaven Road Capital Fund 1.

1
GSAT / Globalstar, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-04-11 fintel.io
Globalstar, Inc. (AMEX:GSAT) has 166 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 1,125,349,130 shares. Largest shareholders include Fl Investment Holdings Llc, Mudrick Capital Management, L.P., Vanguard Group Inc, BlackRock Inc., Warlander Asset Management, LP, Steelhead Partners Llc, HHR Asset Management, LLC, Beck Mack & Oliver Llc, York Capital Management Global Advisors, LLC, and D.

2
NFEC / NF Energy Saving Corp. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-04-11 fintel.io
NF Energy Saving Corp. (NASDAQ:NFEC) has 5 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 2,415,782 shares. Largest shareholders include Liaoning Nengfa Weiye New Energy Application Co Ltd, Renaissance Technologies LLC, Deutsche Bank Ag\, Virtu Financial LLC, and Morgan Stanley.

 
OXSQ / Oxford Square Capital Corp. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-04-11 fintel.io
Oxford Square Capital Corp. (NASDAQ:OXSQ) has 1 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 347,174 shares. Largest shareholders include Rivernorth Capital Management, Llc.

 
HTF / Horizon Technology Finance Corp. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-04-11 fintel.io
Horizon Technology Finance Corp. (NYSE:HTF) has 46 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 2,770,443 shares. Largest shareholders include Compass Horizon Partners, LP, Advisors Asset Management, Inc., UBS Group AG, Bridgeway Capital Management Inc, Guggenheim Capital Llc, Lsv Asset Management, Hillsdale Investment Management Inc.

 
Your Daily Pharma Scoop: vTv Therapeutics Plunges, Spectrum Provides Updated Data, Selecta Sees Pullback On Data

2018-04-11 seekingalpha
Today we will discuss vTv Therapeutics (NASDAQ:VTVT), which has seen three quarters of its market capitalization wiped off after the failure of a late-stage Alzheimer’s study. The failure once again highlights the fact that Alzheimer’s remains a difficult to treat area.

ZYNE: Zynerba Pharmaceuticals Analysis and Research Report

2018-04-08 - Asif

Company Overview Zynerba Pharmaceuticals is a clinical stage specialty pharmaceutical company dedicated to the development and commercialization of innovative transdermal pharmaceutically-produced cannabinoid treatments for rare (meeting the U.S. Food and Drug Administration’s, or FDA’s, designation of an orphan disease, affecting fewer than 200,000 people in the United States) and near-rare (affecting fewer than one million people in the United States) neurological and psychiatric, or neuropsychiatric, disorders in patients with high unmet medical needs. Zynerba Pharmaceuticals is currently evaluating two patent protected product candidates, ZYN002 and ZYN001, in four neuropsychiatric indications. In 2017, the company completed three Phase 2 clinical trials for ZYN002 and two of those studies have open-label extensions that are ongoing. In 2018 the company plan to initiate additional clinical trials evaluating ZYN002 for the treatment of behavioral symptoms of Fragile X syndr...

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 98986X109